There is substantial evidence to suggest that aberrant DNA methylation in the regulatory regions of expressed genes may play a role in hematologic malignancy. In the current report, the Restriction Landmark Genomic Scanning (RLGS) method was used to detect aberrant DNA methylation (M) in acute myeloid leukemia (AML). RLGS-M pro®les were initially performed using DNA from diagnostic, remission, and relapse samples from a patient with AML. Rp18, one of the eight spots found that was absent in the relapse sample, was cloned. Sequence analysis showed that the spot represented a portion of the WIT-1 gene on human chromosome 11p13. Rp18 was missing in the relapse sample due to a distinct DNA methylation pattern of the WIT-1 gene. Twenty-seven AML patients that entered CR after therapy (i.e., chemosensitive) were studied and only 10 (37%) of the diagnostic bone marrow (BM) samples showed methylation of WIT-1. However, seven of eight (87.5%) diagnostic BM samples from primary refractory AML (chemosensitive) showed methylation of WIT-1. The incidence of WIT-1 methylation in primary refractory AML was signi®cantly higher than that noted in chemosensitive AML (P=0.018). Together, these results indicate that RLGS-M can be used to ®nd novel epigenetic alterations in human cancer that are undetectable by standard methods. In addition, these results underline the potential importance of WIT-1 methylation in chemoresistant AML.
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Introduction
Acute myeloid leukemia (AML) is characterized by a variety of recurrent cytogenetic abnormalities that often identify speci®c gene fusions or gene deletions. In addition, molecular defects in AML have now been identi®ed in the absence of clonal chromosomal changes (Caligiuri et al., 1997) . However, in approximately 40% of all patients with AML, a cytogenetic rearrangement is not identi®ed at diagnosis. Further, little is known about the genetic changes associated with primary refractory AML, i.e., AML found in patients who fail to achieve complete remission (CR) following initial chemotherapy. Molecular changes associated with relapsed AML, i.e., AML occurring after achieving CR, are also largely unknown. Aberrant DNA methylation in the regulatory region of certain genes is commonly associated with gene inactivation (Baylin et al., 1998) . Recently, hypermethylation of several established or candidate tumor suppressor genes such as p15, p16 and HIC1 has been demonstrated in hematologic malignancies (Issa et al., 1997a) . However, to date, we know of no investigation of aberrant DNA methylation in primary refractory or relapsed AML.
Restriction Landmark Genomic Scanning (RLGS) is a two-dimensional gel electrophoresis method that allows detection of gross chromosomal rearrangements in human tumors . If methylation sensitive enzymes are used (RLGS-M), the method is able to provide an unbiased search for altered DNA methylation (Plass et al., 1996) . Most of the rare cutting restriction enzyme sites with GC-rich recognition sequences are located in the 5' portions of genes resulting in a selective display of gene sequences rather than random genomic sequences. The sequence of RLGS spots can be determined through standard PCR-based or direct cloning procedures . Up to 2000 endlabeled rare cutting restriction sites are displayed in a single RLGS pro®le. RLGS pro®les are highly reproducible allowing for comparison of dierent tissues [e.g. normal versus tumor tissue (Akama et al., 1997) ] or of dierent individuals. However, to our knowledge, RLGS-M has not been reported to detect DNA methylation in human cancer.
In this study, we successfully used RLGS-M to detect and clone a gene, WIT-1, which showed an altered pattern of methylation in chemotherapy sensitive, primary refractory and relapsed AML.
Results
The RLGS-M analysis was initially performed on three samples obtained from a single AML patient, unique patient number (UPN) 1, at the time of diagnosis, remission and relapse. A total of 1284 spots were analysed in each of the three RLGS-M pro®les ( Figure  1a) . No enhanced spots indicative of DNA amplificaa b Figure 1 (a) RLGS pro®le using DNA from the relapse AML sample of UPN 1. Digestion of the DNA was performed using NotI ± EcoRV ± HinfI restriction enzymes. The molecular sizes for the 1st and 2nd dimensions are illustrated in the top and right margins. Coordinates (B ± D and 1 ± 4) are indicated in the top and left side margins. The location of spots Rp6 (6), Rp11 (11), Rp12 (12) and Rp18 (18) are indicated by arrows. (b) Enlargements of portions of RLGS pro®les from diagnosis, remission and relapse samples of UPN 1, containing RLGS spots Rp6, Rp11, Rp12 and Rp18. These spots were selected to demonstrate the three dierent patterns of RLGS spot changes. In the ®rst pattern, a spot is missing only at relapse (Rp12 and Rp18); in the second pattern, a spot is present with diploid intensity only at diagnosis (Rp11) and in the third pattern, a spot is present only in remission (Rp6) tion or hypomethylation of normally methylated repeat sequences were identi®ed. Thirteen of 1284 spots showed alteration between diagnosis, remission or relapse pro®les, and were categorized into one of three patterns (Figure 1b) . Eight spots were present in diagnostic and remission pro®les but were absent or reduced in intensity in the relapse pro®les (examples are Rp12 and Rp18 in Figure 1b) . Three spots were present in the diagnostic pro®le and missing or reduced in intensity in the remission and relapse pro®les (e.g., Rp11 in Figure 1b) . Two spots were found only in the remission pro®le (e.g., Rp6 in Figure 1b) . The loss of an RLGS-M spot in sequential samples from an individual can be caused by several genetic or epigenetic events. These include the diploid loss of a chromosomal region in which this locus is located, diploid sequence mutations within one of the restriction enzyme sites used in RLGS-M, DNA methylation of both alleles within the restriction landmark site, or by some combination of these events (Akama et al., 1997) .
Since eight out of the total 13 changes were spots absent only in relapse we cloned Rp18, that was missing only in the relapse pro®le ( Figure 1a and b). Sequence analysis of a 221 bp NotI ± HinfI fragment obtained from the cloning procedure showed this to represent a portion of exon 2 in the WIT-1 gene (Gessler and Bruns, 1993) . Using this fragment as a probe, we obtained a homologous 2.25 kb NotI ± EcoRV fragment corresponding to the WIT-1 gene from an arrayed NotI ± EcoRV genomic library . A 700 bp NotI ± EcoRI fragment was then used as a probe for the Southern analysis of diagnosis, remission and relapse AML samples. Genomic DNA was digested with the EcoRV enzyme alone or double digested with EcoRV and the methylation sensitive NotI enzyme. Control DNA digested with EcoRV alone hybridized to the probe above 25 kb, whereas the double digested DNA hybridized to the probe at 2.25 kb. DNA obtained from diagnostic and remission samples of UPN 1 that was digested in a similar fashion showed a pattern of hybridization that was identical to the control DNA. However DNA from the relapse sample of UPN 1 failed to show the 2.25 kb band following the double digest, suggesting that the NotI site might be methylated in this sample (Figure 2 ). Sequence analysis of the NotI site in this region of WIT-1 failed to show any mutation in the relapse sample (not shown), con®rming that the site was methylated.
A series of Southern blot analyses with DNA from the diagnostic, remission, and relapse samples of UPN 1 were performed using the 700 bp EcoRI-NotI fragment as a probe, the published WIT-1 sequence, and double digests with EcoRI and ®ve dierent methylation sensitive, restriction enzymes (NotI, BssHII, SmaI, HpaII and HhaI). Diagnostic and remission samples showed fragment sizes predicted from the published WIT-1 sequence assuming no methylation in exon 2. However, the relapse sample showed fragments consistent with a distinct pattern of DNA methylation within WIT-1 (Figure 3a) . The WIT-1 methylated sites in the relapse sample were restricted to exon 2 and intron 1 (Figure 3b) .
We determined the methylation status of WIT-1 in diagnostic BM samples from 27 AML patients (including UPN 1) that each responded to induction chemotherapy by obtaining a CR, that is chemosensitive AML. Ten of the 27 samples (37%) demonstrated methylation of WIT-1 on Southern analysis. For nine of the 27 cases, additional material was available to study WIT-1 methylation status at relapse. Two of these nine cases showed methylation of WIT-1 at diagnosis and relapse. In three of these cases no methylation was found in diagnosis or relapse. In three cases methylation was exclusively found in the relapse sample and in a single case methylation of WIT-1 was found in the diagnosis sample but not in the relapsed. Importantly, in all samples the pattern of WIT-1 methylation was restricted to exon 2 and intron 1 (not shown). The distinct pattern of WIT-1 methylation in ®ve of nine relapsed AML samples suggested that this pattern might be found with greater frequency in primary refractory AML, that is, patients who fail to achieve a CR following the administration of induction chemotherapy. DNA was obtained from the diagnostic material of eight such patients and subjected to analysis for methylation of WIT-1. Seven of eight (87.5%) cases showed WIT-1 methylation as had been seen in relapsed AML. Indeed, the incidence of WIT-1 methylation in refractory AML was signi®cantly higher than that noted in chemosensitive AML (P=0.018, Fisher's Exact Test). While our small sample size limits statistical power, there was no signi®cant dierence when we compared CR duration in chemosensitive AML patients that lacked methylation of WIT-1 at Figure 2 Southern analysis of DNA samples from normal blood lymphocytes (PBL), diagnosis, remission and relapse AML BM samples from UPN 1. Each DNA sample was digested with EcoRV (7) and with EcoRV and NotI (+). The digests were then hybridized to the 700 bp EcoRI ± NotI fragment probe derived from the WIT-1 region (see Figure 3b for location). Note the absence of a rearranged 2.3 kb band in the relapse AML sample following double digest diagnosis (median 11.8 months) with CR duration in chemosensitive AML patients that showed methylation of WIT-1 at diagnosis (median 11.5 months, P=0.258 by nonparametric Mann ± Whitney U test). Interestingly, two AML cell lines, TI-1 (Taoka et al., 1992) and ML-1 (Palumbo et al., 1984) displayed methylation of WIT-1 in an identical pattern as that seen for all other cases (not shown). We found no evidence for a b Figure 3 (a) Southern analysis of DNA samples extracted from diagnosis, remission and relapse samples of UPN 1. DNA was digested with 1-EcoRI, 2-EcoRI/NotI, 3-EcoRI/BssHII, 4-EcoRI/SmaI, 5-EcoRI/HpaII and 6-EcoRI/HhaI. The digests were then hybridized to the 700 bp EcoRI NotI fragment probe derived from the WIT-1 region. The large fragment in lane 2 in the diagnosis and remission samples is most likely due to incomplete NotI restriction digest (see also Figure 2 ). This (b) Restriction map of the WIT-1/WT1 region. The upper part shows a restriction map for enzymes BglII-B, EcoRI-RI, EcoRV-RV and NotI-N. The presence of additional BglII sites in the large BglII ± EcoRI fragment was not tested. The location of the NotI ± EcoRV boundary clone (pNRVWIT) and the EcoRI ± NotI fragment used as a probe for Southern hybridization is indicated. The bottom part contains a detailed restriction map of the 5.5 kb sequence (Accession number: HSWT1WIT). This map includes the ®rst and second exon of WIT-1 and the ®rst exon of WT1. Location of restriction enzymes sites used to determine the extent of DNA methylation in the relapse sample is shown for NotI (N), BssHII (Bs), SmaI (S), HpaII (vertical dashes above line) and HhaI (vertical dashes below line). The numbered arrowheads indicate the sites that were cut by the methylation sensitive enzymes SmaI and HpaII, HhaI (2) and BssHII (3). The extent of WIT-1 methylation covers exon 2 and intron 1 and is indicated by the lowest black bar (see text for details)
WIT-1 methylation in 10 normal human BM samples analysed by Southern analysis (not shown).
The WIT-1 gene is located approximately 1 kb upstream of the Wilms tumor gene, WT1 (Huang et al., 1990) . Neither gene appears to be expressed in normal adult tissues, although WT1 is frequently expressed in diagnostic (Bergmann et al., 1997) and relapsed AML (Inoue et al., 1997) . We therefore analysed diagnostic, remission and relapsed samples of UPN 1 and the two AML cell lines for expression of these genes. WIT-1 expression was undetectable in any of these samples by reverse transcription PCR, while WT1 expression was found exclusively in the relapsed AML sample of UPN 1 and in the leukemic cell lines (data not shown). In addition we tested a set of seven leukemic samples, with and without WIT-1 methylation, for the expression of WIT-1 and WT1. WIT-1 was not expressed in any sample, and no correlation was found between WIT-1 methylation and WT1 expression. WT1 expression was found in diagnostic samples, independent of WIT-1 methylation, and a relapse sample with WIT-1 methylation did not overexpress WT1 (data not shown).
Discussion
In the current study we demonstrate that RLGS-M can be used to identify aberrant gene methylation in human cancer. There are several potential advantages to using RLGS-M for the discovery of gene methylation when compared with other PCR based methodologies (Gonzalgo et al., 1997; Ushijima et al., 1997) . First, the vast majority of labeled DNA fragments produced in a single 2-dimensional gel are sequences from the 5' end of genes, rather than a random display of DNA from anywhere in the genome. Second, RLGS-M allows the simultaneous detection of rearrangements, mutations, and methylation changes, as gene methylation is one of only three possible explanations to account for the loss of a labeled fragment on comparative RLGS-M analyses from a single individual. Third, it produces over a thousand fragments in a highly reproducible pattern from sample to sample, making it relatively easy to visually detect gene ampli®cation or deletion. Fourth, because of its reproducibility, spot cloning can be facilitated by the use of reference gels with more abundant DNA and further, with established genomic libraries .
Regional hypermethylation of CpG islands in the 5' regulatory regions of expressed genes is a frequently noted modi®cation in neoplastic cells, while most such regions are unmethylated in normal tissues. Promoter hypermethylation in cancer has been associated with inactivation of tumor-suppressor genes such as the retinoblastoma gene, the cyclin-dependent kinase inhibitor genes p15 and p16, the hMLH1 gene, the VHL gene, and HIC-1 (for a review see Baylin et al., 1998) . In leukemia, CpG island hypermethylation in the promoter region of tumor-suppressor and growth control genes has recently been shown to be an important mechanism for gene inactivation (Issa et al., 1997a) . In AML, these genes include the calcitonin gene (Baylin et al., 1986) , the estrogen receptor gene (Issa et al., 1996) , p15 (Herman et al., 1997) and HIC-1 (Issa et al., 1997b) . However, to date, the demonstration of speci®c regional hypermethylation of a gene as a consistent ®nding in refractory or relapsed AML has not, to the best of our knowledge, been reported.
Relapsed AML is likely to result from the selective in vivo outgrowth of leukemogenic stem cells intrinsically resistant to initial induction chemotherapy. In primary refractory AML, the majority of leukemic blasts possess intrinsic resistance even prior to induction chemotherapy. Thus, primary refractory and relapsed AML may, in some instances, share common genetic alterations important in drug resistance. In the current study, we utilized RLGS-M to identify a gene, WIT-1, that was normal in a diagnostic AML and CR sample, yet was speci®cally hypermethylated within exon 2 and intron 1 in a relapse sample from the same patient. We then found WIT-1 methylated in 37% of newly diagnosed cases of chemosensitive AML, all of whom achieved CR, and in 87.5% of primary refractory AML, none of whom achieved CR. WIT-1 was methylated in ®ve out of nine AML patient samples obtained at the time of relapse. Thus, methylation of WIT-1 might have an association with chemoresistant AML. A larger analysis of WIT-1 hypermethylation in AML will need to be performed in a prospective fashion to determine if these early observations of this epigenetic alteration can be con®rmed.
It is interesting to note that WIT-1 like the calcitonin gene, maps to human chronosome 11p, a chromosomal area in which several human tumor suppressor genes are localized. It was speculated that this chromosomal region behaves like a`hot-spot' for aberrant DNA methylation in various human tumors (Baylin et al., 1998; deBustros et al., 1988) . In addition, this chromosomal area coincides with the presence of several imprinted genes (Jinno et al., 1994; Tycko, 1994) , for which allele-speci®c methylation is one of the suggested regulatory mechanisms (Neumann et al., 1995) .
The product and role of WIT-1 in normal development or malignant transformation are unknown. It is located approximately 1 kb upstream of the Wilms tumor suppressor gene, WT1, and appears to be expressed coordinately with WT1 during kidney development and in Wilms tumor. There is evidence that WT1 and WIT-1 are bidirectionally transcribed from the same promoter region (Gessler and Bruns, 1993; Huang et al., 1990) . Interestingly, despite its extremely restricted pattern of expression in normal tissues, WT1 is overexpressed in AML (Inoue et al., 1997) . WT1 antisense can inhibit growth of human leukemic cells, suggesting that overexpression of WT1 has a role in leukemogenesis (Yamagami et al., 1996) . The regulatory mechanism(s) of WT1 overexpression in AML remain undetermined, but our data appear to exclude the possibility that methylation in the upstream WIT-1 region is involved in the regulation of WT1). In a recent paper, Hiltunen et al. (1997) describe the hypermethylation in the promoter of the WT1 gene in colon cancers. WT1 expression was found not to be altered between normal colonic mucosa and malignant carcinoma, suggesting that the regulatory mechanism for WT1 expression does not include DNA methylation of its promoter region.
In summary, RLGS-M has been used to identify a gene, WIT-1, that undergoes a speci®c pattern of DNA methylation during the development and progression of AML, and has a signi®cantly higher incidence of methylation in refractory AML. It appears likely that this technique can be successfully employed to identify additional genes undergoing methylation or demethylation at diagnosis or during the progression of human cancer. Such advances should further our understanding of the genetic and epigenetic events involved in malignant transformation.
Materials and methods

Patient samples and cell lines
Bone marrow (BM) samples were obtained from patients with a diagnosis of AML based on standard French ± American ± British (FAB) morphological and cytochemical criteria (Bennett et al., 1985) . All patients provided informed consent according to institutional guidelines. Response criteria were de®ned according to the recommendations of the National Cancer Institute-sponsored workshop on de®nitions of diagnosis and response in AML (Cheson et al., 1990) . Primary refractory AML was de®ned as histologic evidence of persistent AML in patients surviving initial induction chemotherapy. Patient BM cells were thawed (470% viability) and prepared for DNA extraction according to an established protocol (Sambrook et al., 1989) . DNA was also extracted from two established AML cell lines TI-1 (Taoka et al., 1992) and ML-1 (Palumbo et al., 1984) .
RLGS-M
RLGS-M was performed according to our published protocol (Okazaki et al., 1995) . Brie¯y, to prevent nonspeci®c labeling, the sheared ends of the sample DNA were blocked by the addition of nucleotide analogs (aS-dGTP, aS-dCTP, ddATP, ddTTP). The DNA was then digested with 20 U NotI (Promega, Madison, WI, USA) and the resulting restriction sites were end-labeled in a ®ll-in reaction. The labeled DNA was digested with 20 U EcoRV (Promega) and 1.5 mg were electrophoresed through an 0.8% agarose tube gel (®rst dimension separation). The DNA was digested in the gel with 750 U HinfI (Promega) and electrophoresed in a 5% polyacrylamide gel (second dimension separation). The gel was next dried and exposed to Kodak X-OMAT AR ®lm in the presence of one Quanta III, intensifying screen, (DuPont, Boston, MA, USA) for 2 ± 10 days.
RLGS-M spot cloning
DNA sequences corresponding to RLGS-M spots were cloned as previously described . NotI ± EcoRV fragments were enriched from 500 mg total genomic DNA derived from a normal individual using the NotI restriction trapper puri®cation. One ®fth of the puri®ed material was endlabeled, mixed with the unlabeled portion and subjected to RLGS-M gel electrophoresis. RLGS-M spot Rp18, ®rst identi®ed using diagnostic material from UPN 1, was located on the acrylamide gel prepared from normal DNA, excised, electroeluted, and dissolved in TE buer. NotI and HinfI adapters were ligated to the ends of the fragment to allow a nested PCR with primers speci®c for the adapter sequences. PCR products were cloned into a TA cloning vector (Invitrogen, San Diego, CA, USA).
Southern analysis
Five mg of genomic DNA were digested with 20 ± 30 U of each restriction enzyme as indicated and DNA fragments were separated by 0.8 ± 1.5% agarose gel electrophoresis. Transfer, hybridization and probe labeling were performed using established methods (Sambrook et al., 1989) .
